Senator Ted Cruz, R-Texas, has reintroduced a bill he thinks will speed US approval of drugs, biologics, or devices approved in other countries.
Senator Ted Cruz, R-Texas, reintroduced a bill he thinks will speed US approval of drugs, biologics, or devices approved in other countries.
The bill, called Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act, or the RESULTS Act, would give the Food and Drug Administration (FDA) 30 days after a company sends in an application to decide whether it wants to greenlight a drug, device, or biologic approved in another country.
It’s at least the third time Cruz has introduced the bill (the last 2 times were in 2015 and 2017), which would give Congress the power to override an FDA rejection of a product. The 2 other cosponsors are Senators Ron Johnson, R-Wisconsin, and Mike Lee, R-Utah.
Cruz has said the bill could put downward pressure on the prices of drugs and devices as well as alleviate drug shortages.
The bill orders the FDA to review drug and device applications within 30 days and allow “reciprocal approval” of therapies from the European Union, Israel, Australia, Canada, and Japan.
In previous years, health advocates and FDA observers have noted pitfalls with the idea. For one thing, the idea of giving a political body such as Congress the power to overrule the FDA’s scientific experts on matters relating to public health, safety, efficacy, science, and other concerns raises major concerns.
Cruz, like some other conservatives, say that US patients don’t have speedy access to possible life-saving treatments. In a previous press release about the RESULTS Act, he said it is time for a “supply-side medical revolution.”
Last year, conservatives saw one related victory with the passage of the so-called right-to-try law. The Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 creates an alternative pathway for dying patients who do not qualify for a clinical trial. The law bypasses the FDA's current expanded access and compassionate use programs and allows patients to appeal directly to drug companies.
That law, too, was based on the idea that the FDA does not move quickly enough.
The FDA approved 59 drugs in 2018, compared with 46 in 2017. Other studies have said that the FDA acts on applications more quickly than other regulatory authorities.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.